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Summary
Background Hereditary hemorrhagic telangiectasia is
an inherited autosomal dominant disease presenting
with recurrent bleeding episodes and iron deficiency
anemia due to vascular malformations. Hereditary
hemorrhagic telangiectasia is associated with an in-
creased risk of stroke, gastrointestinal bleeding and
pulmonary hypertension and life expectancy is signif-
icantly reduced. Excess vascular endothelial growth
factor (VEGF) plays a key role in the pathophysiology
of the disease.
Case presentation Here we report about a male patient
with hereditary hemorrhagic telangiectasia presenting
with pulmonary and central nervous system involve-
ment experiencing repetitive nosebleeds, necessitat-
ing frequent local cauterization and transfusion of
more than 100 units of packed red blood cells. After
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initiation of temporary therapy with the anti-VEGF
antibody bevacizumab at a dosage of 1 mg/kg body
weight every 2 weeks, the nose bleeding episodes and
the epistaxis severity score significantly decreased and
long-lasting transfusion independence was achieved.
Reinitiation of low-dose bevacizumab after relapse
again proved effective without any documented ther-
apy-related adverse events. In comparison to other
reported anti-VEGF antibody protocols in hereditary
hemorrhagic telangiectasia, our treatment approach
proved to be cost-efficient.
Conclusion Intermittent low-dose therapy with be-
vacizumab represents an effective and cost-efficient
treatment option for transfusion-dependent patients
with hereditary hemorrhagic telangiectasia.
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Introduction
Hereditary hemorrhagic telangiectasia (HHT) is a ge-
netic disorder inherited in an autosomal dominant
manner and caused by mutations in the genes encod-
ing endoglin and activin receptor-like kinase type 1
[1, 2]. The syndrome is characterized by the presence
of telangiectasia and arteriovenous malformations
(AVM) and an increased vulnerability of these vascular
structures causing recurrent hemorrhagic episodes.
Most patients suffering from HHT initially present
with severe recurrent nosebleeds in early childhood
requiring local measures, such as electrocoagulation,
oral or intravenous iron substitution or even frequent
transfusion of packed red blood cells (RBC). The find-
ing of increased plasma levels of vascular endothelial
growth factor (VEGF) in HHT patients provided the
basis for targeting VEGF in this syndrome of unbal-
anced angiogenesis as previously reported [3–5].
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Case presentation
In February 2014 a 57-year-old male patient diag-
nosed with HHT and suffering from recurrent nose-
bleeds since childhood was referred to our clinic. The
definitive diagnosis was established at the age of 43
years by fulfilling each of the 4 proposed Curaçao
criteria: (1) spontaneous and recurrent nosebleeds,
(2) presence of telangiectasia, (3) presence of AVM and
(4) positive family history [6]. In the past years, the
nose bleeding episodes had dramatically increased
necessitating multiple nasal cauterization and trans-
fusion of more than 100 units of packed RBC between
January 2009 and February 2014. At the initial pre-
sentation at our clinic, we observed severe anemia
with a hemoglobin level of 5.1 g/dl as well as hypo-
ferritinemia (4 µg/l) requiring continuation of RBC
transfusions as well as oral iron supplementation.
Further endoscopic and imaging measures also re-
vealed disease involvement of the duodenum, lungs
and medulla oblongata. Due to the high frequency
of nosebleeds associated with symptomatic anemia
requiring RBC transfusions every 14 days and mul-
tivisceral disease involvement, intravenous systemic
therapy with the anti-VEGF antibody bevacizumab
was started in March 2014 and administered every 2
weeks at a dose of 1 mg/kg body weight after obtain-
ing the patient’s informed consent including the off-
label use of bevacizumab in HHT. Within several days
after the first injection of bevacizumab the severity
and duration of nosebleeds impressively decreased.
The epistaxis severity score (ranging from 0 to 10),
a tool to standardize the severity of nosebleeds, was
decreased from nine to two and was maintained
beyond cessation of anti-VEGF therapy [7]. Beva-
cizumab therapy had been started at a hemoglobin
level of 7.6 g/dl and after the application of 16 cy-
cles (=32 weeks) a hemoglobin level of more than
13 g/dl was achieved. The therapy was stopped in
October 2014 whereas oral iron supplementation was
continued.
The size of the pulmonary and central nervous sys-
tem AVM had not changed during anti-VEGF treat-
ment in imaging studies but the nasal mucosa be-
came pale and less vascular. In May 2015, 7 months
after stopping bevacizumab, the severity of the nose-
bleeds gradually increased again and due to symp-
tomatic anemia (hemoglobin 6.8 g/dl) the patient was
transfused with RBC again; however, between October
2014 and May 2015 our patient had remained inde-
pendent of RBC transfusions for 258 days. As a conse-
quence of the recurrence of heavy nosebleeds, we de-
cided to reinitiate therapy with low-dose bevacizumab
for another seven cycles in May 2015 which imme-
diately shortened the duration of epistaxis episodes
and led to a RBC transfusion independence for a fur-
ther 181 days. Anti-VEGF treatment was reinitiated in
November 2015 due to a progressive relapse of severe
nosebleeds. Since January 2016 our patient has been
transfusion-independent and anti-VEGF therapy was
recently stopped in May 2016 after 13 therapy cycles
(Fig. 1). The patient’s epistaxis severity score has cur-
rently improved to one. To date, the patient has not
experienced any therapy-related adverse events.
Discussion
Temporary targeting of VEGF with low-dose beva-
cizumab resulted in an impressive decrease in the
severity of epistaxis thereby achieving transfusion-in-
dependent intervals of 258 and 181 days on initiation
and reinitiation of systemic low-dose bevacizumab
therapy and the patient is currently RBC transfu-
sion-independent. Considering the off-label status of
bevacizumab in HHT, we decided to use the mon-
oclonal antibody at a lower dose of 1 mg/kg body
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weight every 14 days in contrast to a dose of 5 or
10 mg/kg body weight as previously reported [4, 5].
Low-dose bevacizumab as treatment for HHT has
only been used in a few case reports and case series
so far. Thompson et al. prospectively demonstrated
an improvement of the epistaxis severity score in
a case series with six patients and very low-dose be-
vacizumab (0.125 mg/kg body weight every 4 weeks)
without affecting hemoglobin levels [8]. While several
reports show a decrease of the severity and frequency
of nosebleeds with low-dose bevacizumab (at doses
of 1–2 mg/kg body weight applied every 2–3 weeks),
rapid relapses are reported after cessation of anti-
VEGF therapy without reporting about long-term fol-
low-up [9, 10]. The effectiveness of continued low-
dose bevacizumab treatment (1 mg/kg body weight
every 3 weeks) was demonstrated in an HHT patient
who had initially been treated with bevacizumab at
5 mg/kg body weight and then relapsed [11].
The total costs of our treatment approach over
a time course of 2 years and according to Austrian
prices were less than half compared to the costs
for bevacizumab therapy with 5 mg/kg body weight
( 20,263.88 versus  43,422.60) [5]. The estimated
costs of continued RBC transfusions over the same
time with a transfusion interval of 14 days would
have been  13,728.00. This treatment approach
might pose a threat to patients in terms of the de-
velopment of alloantibodies and an increased risk of
infections. When comparing the costs between a con-
tinued low-dose bevacizumab regimen and an inter-
mittent low-dose bevacizumab therapy over 2 years
( 37,632.92 versus  20,263.88), the latter proves to
be cost-efficient and causes the least cumulative drug
exposure [11]. Before initiating treatment with beva-
cizumab, we assessed the patient history for previous
thromboembolic events, diabetes mellitus and age
(>65 years) and weighed the potential benefit against
a significantly increased risk of thromboembolism.
We monitored potential bevacizumab-induced side
effects by daily blood pressure measurements and
biweekly urinalyses for proteinuria.
As increased plasma levels of VEGF play a key role
in the pathophysiology of HHT, several other mon-
oclonal antibodies that target the VEGF signalling
pathway, such as aflibercept and ramucirumab or
downstream VEGF tyrosine kinase inhibitors, such
as cediranib or sunitinib might serve as potential
treatment approaches in HHT; however, so far, only
one case report demonstrating a reduction of the
epistaxis frequency and intensity in an HHT pa-
tient during treatment with sunitinib (37.5 mg orally
once daily in a 4-week on/2-week off schedule) for
metastatic renal cell carcinoma has been published
without reporting on adverse events, such as hand-
foot syndrome or gastrointestinal side effects. It is
noteworthy that the benefit of epistaxis control de-
creased during the 2-week off treatment period [12].
Among VEGF or VEGF receptor targeting monoclonal
antibodies, aflibercept has been associated with an
increased incidence of hypertension in comparison
to bevacizumab and ramucirumab in the treatment
of metastatic colorectal cancer [13].
In summary, we show that intermittent low-dose
systemic therapy with bevacizumab yields satisfactory
transfusion-independent time intervals and demon-
strates a valuable treatment option for HHT patients
who suffer from severe bleeding episodes. Therapy
responses can also be expected on retreatment with
low-dose bevacizumab in relapsing patients. Apart
from economic considerations, intermittent low-dose
bevacizumab therapy might reduce the risk of known
dose-dependent anti-VEGF-induced side effects, such
as hypertension, proteinuria and bleeding [14].
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